MSAC - 1686.1 –177 Lutetium PSMA i&t for metastatic castrate resistant prostate cancer
Description of Medical Service177Lutetium PSMA i&t is a targeted radionuclide radiotherapy that enters the cancer cell via the PSMA receptor, which is overexpressed in prostate cancer, with expression increasing in metastatic and castrate resistant disease. Therapy is intended for patients with progressive metastatic castrate resistant prostate cancer after the disease has progressed despite chemotherapy. Screening with PSMA Positron Emission Tomography (PET) and FDG PET determines if the patient has an adequate level of PSMA ‘target’ at all sites of measurable disease such that they will be expected to derive significant benefit from the treatment.
Description of Medical ConditionProstate cancer is one of the commonest cancers in Australia. Castrate-resistant prostate cancer is defined by disease progression despite androgen depletion therapy (reducing the amount of testosterone in the body) and may present as either a continuous rise in serum prostate-specific antigen levels (usually elevated in men with prostate cancer), the progression of pre-existing disease, and/or the appearance of new metastases.
Reason for ApplicationNew MBS item
Medical Service TypeTherapeutic technology
Previous Application Number/s1686
Application FormApplication Form (PDF 1920 KB)
Application Form (Word 1617 KB)
Consultation SurveyConsultation Survey (PDF 652 KB)
Consultation Survey (Word 27 KB)
MSAC consultation input must be received by no later than Friday, 16 February 2024 for it to be considered by MSAC at its April 2024 meeting.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process
Public Summary DocumentPublic Summary Document (PDF 570 KB)
Public Summary Document (Word 145 KB)
Meetings for this Application
ESC8-9 June 2023
15-16 February 2024
MSAC27-28 July 2023
4-5 April 2024